Skip to Content
Merck
  • Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.

Synthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents.

Bioorganic & medicinal chemistry letters (2008-09-23)
Sudhir N Bavikar, Deepak B Salunke, Braja G Hazra, Vandana S Pore, Robert H Dodd, Josiane Thierry, Fazal Shirazi, Mukund V Deshpande, Sreenath Kadreppa, Samit Chattopadhyay
ABSTRACT

Tetrapeptides derived from glycine and beta-alanine were hooked at the C-3beta position of the modified cholic acid to realize novel linear tetrapeptide-linked cholic acid derivatives. All the synthesized compounds were tested against a wide variety of microorganisms (gram-negative bacteria, gram-positive bacteria and fungi) and their cytotoxicity was evaluated against human embryonic kidney (HEK293) and human mammary adenocarcinoma (MCF-7) cell lines. While relatively inactive by themselves, these compounds interact synergistically with antibiotics such as fluconazole and erythromycin to inhibit growth of fungi and bacteria, respectively, at 1-24 microg/mL. The synergistic effect shown by our novel compounds is due to their inherent amphiphilicity. The fractional inhibitory concentrations reported are comparable to those reported for Polymyxin B derivatives.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Gly-Gly-Gly-Gly
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Cholic acid, from bovine and/or ovine, ≥98%
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.